Blueprint Medicines Corp (BPMC)
94.15
-2.47
(-2.56%)
USD |
NASDAQ |
Nov 22, 16:00
94.20
+0.05
(+0.05%)
After-Hours: 20:00
Blueprint Medicines Revenue (Quarterly): 128.18M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 128.18M |
| June 30, 2024 | 138.16M |
| March 31, 2024 | 96.12M |
| December 31, 2023 | 71.96M |
| September 30, 2023 | 56.57M |
| June 30, 2023 | 57.57M |
| March 31, 2023 | 63.29M |
| December 31, 2022 | 38.78M |
| September 30, 2022 | 65.98M |
| June 30, 2022 | 36.55M |
| March 31, 2022 | 62.73M |
| December 31, 2021 | 107.02M |
| September 30, 2021 | 24.19M |
| June 30, 2021 | 27.30M |
| March 31, 2021 | 21.58M |
| December 31, 2020 | 34.11M |
| September 30, 2020 | 745.12M |
| June 30, 2020 | 8.343M |
| March 31, 2020 | 6.167M |
| December 31, 2019 | 51.53M |
| Date | Value |
|---|---|
| September 30, 2019 | 9.139M |
| June 30, 2019 | 5.11M |
| March 31, 2019 | 0.73M |
| December 31, 2018 | 1.033M |
| September 30, 2018 | 1.095M |
| June 30, 2018 | 41.44M |
| March 31, 2018 | 0.954M |
| December 31, 2017 | 1.628M |
| September 30, 2017 | 8.068M |
| June 30, 2017 | 5.89M |
| March 31, 2017 | 5.84M |
| December 31, 2016 | 7.691M |
| September 30, 2016 | 6.16M |
| June 30, 2016 | 7.065M |
| March 31, 2016 | 6.856M |
| December 31, 2015 | 4.635M |
| September 30, 2015 | 3.426M |
| June 30, 2015 | 2.687M |
| March 31, 2015 | 0.652M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
6.167M
Minimum
Mar 2020
745.12M
Maximum
Sep 2020
92.06M
Average
57.07M
Median
Revenue (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 745.74M |
| Regeneron Pharmaceuticals Inc | 3.721B |
| NovaBay Pharmaceuticals Inc | 2.441M |
| Palatin Technologies Inc | -- |
| iBio Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -56.28M |
| Total Expenses (Quarterly) | 177.16M |
| EPS Diluted (Quarterly) | -0.89 |
| Enterprise Value | 5.633B |
| Gross Profit Margin (Quarterly) | 98.49% |
| Profit Margin (Quarterly) | -43.90% |
| Earnings Yield | -2.24% |
| Normalized Earnings Yield | -5.126 |